GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Net Income (Continuing Operations)

SSY Group (HKSE:02005) Net Income (Continuing Operations) : HK$1,076 Mil (TTM As of Dec. 2024)


View and export this data going back to 2005. Start your Free Trial

What is SSY Group Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. SSY Group's Net Income (Continuing Operations) for the six months ended in Dec. 2024 was HK$378 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$1,076 Mil.


SSY Group Net Income (Continuing Operations) Historical Data

The historical data trend for SSY Group's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group Net Income (Continuing Operations) Chart

SSY Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 610.82 788.29 1,189.55 1,329.29 1,075.61

SSY Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 578.07 649.51 679.78 697.79 377.82

SSY Group Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,076 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SSY Group  (HKSE:02005) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


SSY Group Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of SSY Group's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


SSY Group Business Description

Industry
Traded in Other Exchanges
N/A
Address
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.
Executives
China Pharmaceutical Company Limited 2101 Beneficial owner
Qu Jiguang 2201 Interest of corporation controlled by you
Ubs Group Ag 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner

SSY Group Headlines

No Headlines